Aarti Drugs Q3 FY26 Earnings Call Transcript Released
Aarti Drugs released its Q3 FY26 earnings call transcript. Consolidated revenue grew 8% YoY to ₹602.9 Cr. PAT surged 58% YoY to ₹40.5 Cr. The company saw 7% volume growth in standalone business and expects improved performance due to capacity ramp-up and focus on formulations and exports.
The release of the Q3 FY26 earnings call transcript provides detailed insights into the company's performance, challenges, and future outlook. This information is crucial for investors to assess the company's financial health and strategic direction, thus having a medium impact.
The company released its Q3 FY26 earnings call transcript. While there were some positive developments like revenue growth and PAT increase, EBITDA declined YoY due to various operational headwinds. The overall sentiment is neutral as the company is navigating challenges while expecting future improvements.
Aarti Drugs Limited has released the transcript of their Q3 and 9M FY26 Earnings Conference Call, which took place on February 4, 2026. The call featured management including Mr. Adhish Patil (COO & CFO), Mr. Harshit Savla (Joint Managing Director), and Mr. Harit Shah (Whole-Time Director).
During the call, management discussed various factors impacting the quarter's performance, including low utilization levels, weaker antibiotic demand, delays in shipments from China, a voluntary plant shutdown for refurbishment, and new greenfield facilities operating below optimal utilization. On a positive note, the company reported a 7% volume growth in its standalone business segment and a negative rate variance of around 5% year-on-year. Export markets, particularly formulations, were highlighted as key growth drivers.
The Sayakha facility, operational since September 2025, achieved 30% utilization in its first quarter and is expected to reach 50% by March/April 2026. The facility is set to significantly enhance supply reliability for critical intermediates used in their antidiabetic portfolio. The Salicylic acid facility at Tarapur has scaled production to over 300 tons per month, with further improvements planned.
Financially, consolidated revenue for Q3 FY26 stood at ₹602.9 crores, an 8% increase year-on-year. EBITDA was ₹56.3 crores, down 10% year-on-year, with an EBITDA margin of 9.3%. PAT increased by 58% year-on-year to ₹40.5 crores, with a PAT margin of 6.7%. For the 9-month period of FY26, revenue grew 8% to ₹1,846.6 crores, EBITDA increased by 9% to ₹215.0 crores (11.6% margin), and PAT rose by 49% to ₹139.7 crores (7.6% margin).
The formulations business showed encouraging traction, especially in exports, contributing 67% to its revenue. The company is focusing on niche categories like oncology and cardio-diabetic ranges for formulations, with dedicated capacity for oncology.
Management expressed confidence in a more positive trajectory for the coming quarters, with January sales showing an encouraging trend. Future focus remains on capacity ramp-up, operational efficiency, and margin improvement, while maintaining capital discipline and regulatory compliance. The company anticipates a more pronounced impact on financial performance in upcoming quarters as capacity utilization scales up and the enhanced product mix drives higher profitability.
What to do with a filing like this
Aarti Drugs Limited filed this with the NSE as a statutory disclosure, categorised under concall scheduled. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Aarti Drugs Limited. Read the original for the full detail.